Chia Tai Tianqing Pharmaceutical Group Co. Ltd. has disclosed proteolysis targeting chimeric (PROTAC) compounds comprising a E3 ubiquitin ligase-binding moiety covalently linked to an estrogen receptor-α (ERα)-targeting moiety. They are reported to be useful for the treatment of breast cancer.
Breast cancer is the most frequently diagnosed malignancy worldwide. Inhibiting PARP-mediated DNA repair has emerged as a promising anticancer strategy, with PARP inhibitors (PARPis) demonstrating clinical efficacy particularly in tumors with defective homologous recombination repair, such as BRCA-deficient cancers.
Recent evidence has suggested threonine tyrosine kinase (TTK) as a crucial element of the mitotic checkpoint for the correct functioning of spindle assembly checkpoint (SAC), making it a potential therapeutic target in cancer.
Bio-Thera Solutions Ltd. has synthesized new antibody-drug conjugates comprising trastuzumab targeting HER2 (erbB2) covalently linked to exatecan through a linker reported to be useful for the treatment of cancer, inflammation, autoimmune disorders and infections.
Lunan New Time Biotechnical Co. Ltd. has identified new camptothecin derivatives and their antibody-drug conjugates reported to be useful for the treatment of cancer.
Ervimmune SAS has announced the first closing of its series A financing with €17 million ($19.8 million) raised to advance ErVac-01, Ervimmune’s lead candidate, into the clinic and through a first-in-human trial.
Boundless Bio Inc. has obtained IND approval from the FDA for its novel kinesin oral degrader program, BBI-940. A first-in-human trial (KOMODO-1) for metastatic breast cancer is expected to begin in the first half of this year.
Triple-negative breast cancer (TNBC) lacks hormone receptors and HER2 amplification, limiting the effectiveness of targeted therapies and contributing to its aggressive clinical behavior. As aberrant activation of STAT3 is a key driver of TNBC growth, strategies aimed at suppressing STAT3 signaling are emerging as a potential treatment approach.
